Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

SORL

  • Home
  •  
  • SORL



  • Most Read
  • Latest Comments
  • Damaged nerves? Soft tissue regeneration can do a better job than sutures, says Orthocell
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Damaged nerves? Soft tissue regeneration can do a better job than sutures, says Orthocell
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • Damaged nerves? Soft tissue regeneration can do a better job than sutures, says Orthocell
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Damaged nerves? Soft tissue regeneration can do a better job than sutures, says Orthocell
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • Damaged nerves? Soft tissue regeneration can do a better job than sutures, says Orthocell
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • Damaged nerves? Soft tissue regeneration can do a better job than sutures, says Orthocell
    Damaged nerves? Soft tissue regeneration can do a better job than sutures, says Orthocell
    • News

  • OrthoATI trials bring positive results for rotator cuff tendonitis patients, eyes US market
    OrthoATI trials bring positive results for rotator cuff tendonitis patients, eyes US market
    • News

  • Why Orthocell has blown my mind this morning
    Why Orthocell has blown my mind this morning
    • Opinion

  • Patents granted for Orthocell’s suture-less method of soft tissue repair
    Patents granted for Orthocell’s suture-less method of soft tissue repair
    • News

  • Orthocell on commercialisation path following revolutionary tendon regeneration trials
    Orthocell on commercialisation path following revolutionary tendon regeneration trials
    • News

  • Damaged nerves? Soft tissue regeneration can do a better job than sutures, says Orthocell
    • News

    Damaged nerves? Soft tissue regeneration can do a better job than sutures, says Orthocell

    Imagine being in a paralysing accident and then being able to use your limbs like before in little time. Not even movies often consider that possibility. That’s exactly what Western Australia-based regenerative medicine company Orthocell (ASX: OCC) aims to achieve with its product, Remplir, which replaces painful sutures with its soft tissue regeneration medical device.

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.